Últimas noticias sobre Avenue Therapeutics (NASDAQ:ATXI) Bolsa

Avenue Therapeutics

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Avenue Therapeutics Inc

Dividends

JILL

J.Jill's Board Increases Quarterly Dividend By 14.3% To $0.07

Guidance

General Mills Expects FY25 Adjusted EPS To Be Down 8% - Down 7% In CC Vs Previous Range Of Down 4% - Down 2% In CC, Reflecting Lower Sales

BDRX

Biodexa Pharmaceuticals Is Making Progress In Readying The Launch Of A Phase 3 Trial For Erapa, Its Proprietary Encapsulated Form Of Rapamycin Being Developed For The Treatment Of Familial Adenomatous Polyposis

Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) reported quarterly sales of $327.73 million which beat the analyst consensus estimate of $294.60 million by 11.25 percent. This is a 20.54 percent increase over sales of $271.88 million the same period last year.

Earnings

Earnings Beats

SRAD

Sportradar Gr Q4 Sales $327.73M Beat $294.60M Estimate

Asset Sales

SUUN

Solarbank Announce That Its 3.26 MW Camillus Solar Project Has Been Sold To, And Will Now Be Constructed For, Solar Advocate Development In A Transaction Valued At $7.3M

Health Care

General

UnitedHealth's Optum Rx Says It Is Eliminating Up To 25% Of Reauthorizations, Which Is Equal To More Than 10% Of Overall Pharmacy Prior Authorizations, The Initiative Focuses First On Approximately 80 Drugs, And Optum Rx Will Work With Physicians And Pharmacists To Expand The List Over Time

KMDA

Kamada Opens New Plasma Collection Center With Planned Annual Collection Capacity Of Approximately 50,000 Liters; Estimates Annual Revenue Contribution From Sales Of Normal Source Plasma  $8M-$10M At Full Capacity

Merck Announced That Health Canada Approved Keytruda (Pembrolizumab), Merck's Anti-PD-1 Therapy, In Combination With Carboplatin And Paclitaxel, Followed By Keytruda As A Single Agent, For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Carcinoma

Upon closing, the acquisition will provide a number of key benefits: &nbsp; &nbsp;
<ul>
<li>Enhances margins: Immediately accretive to Sportradar's adjusted EBITDA margins, aligning with our disciplined investment approach;&nbsp;</li>
<li>Accelerates growth: Further accelerates Sportradar's robust revenue, adjusted EBITDA and cash flow growth;&nbsp;&nbsp;</li>
<li>Unique structure: Sportradar will not be required to pay any financial consideration; Transaction provides financial consideration totaling $225 million comprised of $125 million paid to Sportradar and up to $100 million cash prepayments made by Endeavor to certain of the sports rightsholders; &nbsp;</li>
<li>Highly strategic portfolio: Basketball, soccer and tennis account for approximately 70% of the rights which are the top three most bet on global sports, complementing our existing sports portfolio.&nbsp;</li>
</ul>

Sportradar To Acquire IMG ARENA And Its Global Sports Betting Rights For $225M, Deal Expected to Close in Q4 2025

General Mills Expects FY25 Organic Net Sales To Be Down 2% - Down 1.5% Vs Previous Expectation Of Lower End Of Flat - Up 1% Range

HC Wainwright &amp; Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Buy and lowers the price target from $9 to $8.

Price Target

Analyst Ratings

ALLO

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $8

Biotech

BDTX

Black Diamond Therapeutics And Servier Announce A Global Licensing Agreement For BDTX-4933 For Solid tumors; Servier Will Develop And Commercialize BDTX-4933, Black Diamond To Receive $70M Upfront Payment And Up To $710M In Milestones

FINANCIAL GUIDANCE
HUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its strong balance sheet. The Company will continue to be financially self-reliant while supporting investments to bring innovative medicines to patients globally.

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

ALTR

NVDA

Altair Announced A Technical Integration Between The NVIDIA Omniverse Blueprint For Real Time Digital Twins And The Altair One Cloud Innovation Gateway

MDWD

MediWound Expects 2025 Sales Of $25M Versus Consensus Of $24.98M

AEVA

Aeva Announced That A Global Top 10 Passenger OEM Has Awarded Aeva A Development Program For Its Next-generation Global Vehicle Platform

In addition, the company plans to make investments in the fourth quarter in advance of significant fiscal 2026 new product launches

General Mills Expects Macroeconomic Uncertainty To Continue To Impact Consumers In Q4

Signet Jewelers Sees FY26 Adj EPS Of $7.31 - $9.10 Vs. $9.00 Est.

HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) reported quarterly earnings of $0.22 per share. This is a 62.07 percent decrease over earnings of $0.58 per share from the same period last year. The company reported $630.20 million in sales this quarter. This is a 24.80 percent decrease over sales of $838.00 million the same period last year.

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

HC Wainwright &amp; Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Buy and maintains $10 price target.

Reiteration

CATX

HC Wainwright & Co. Reiterates Buy on Perspective Therapeutics, Maintains $10 Price Target

Press Releases

Avenue Therapeutics Announces Reverse Stock Split

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Comments

Avenue Therapeutics

Noticias

Últimas noticias sobre Avenue Therapeutics (NASDAQ:ATXI) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL